ACM
SRPT icon

ADAR1 Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

ADAR1 Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-55,000
Closed -$941K – 258
2025
Q2 		$941K Buy
+55,000
New +$2.35M 0.14% 87
2024
Q2 		– Sell
-1,200
Closed -$155K – 310
2024
Q1 		$155K Buy
+1,200
New +$147K 0.04% 129

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ADAR1 Capital Management's SRPT Position: Q1 2026 in Review

ADAR1 Capital Management increased its Sarepta Therapeutics (SRPT) stake by 808% in Q1 2026, buying an estimated $4.51M and bringing the position to 262,058 shares worth $5.7M. The position accounts for 0.34% of the portfolio, ranked #69.

ADAR1 Capital Management first reported a position in SRPT in Q4 2023 and has held it in 10 quarters since. The position peaked at $7.84M in Q1 2025. 340 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • ADAR1 Capital Management held 262,058 shares of Sarepta Therapeutics worth $5.7M as of Q1 2026.
  • ADAR1 Capital Management bought 233,192 Sarepta Therapeutics shares in Q1 2026, an estimated $4.51M.
  • Sarepta Therapeutics made up 0.34% of ADAR1 Capital Management's portfolio in Q1 2026, its #69 holding.
  • ADAR1 Capital Management first reported a position in Sarepta Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • ADAR1 Capital Management's Sarepta Therapeutics position peaked at $7.84M in Q1 2025.
  • 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.